Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Bevacizumab In Combination With Oxaliplatin, Fluorouracil, And Leucovorin (FOLFOX4) For Previously Treated Metastatic Colorectal Cancer: Results From The Eastern Cooperative Oncology Group Study E3200.

B. Giantonio, P. Catalano, N. Meropol, P. O'dwyer, E. Mitchell, S. Alberts, M. A. Schwartz, A. Benson
Published 2007 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
PURPOSE Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer. This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer. PATIENTS AND METHODS Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone. The primary end point was overall survival, with additional determinations of progression-free survival, response, and toxicity. RESULTS The median duration of survival for the group treated with FOLFOX4 and bevacizumab was 12.9 months compared with 10.8 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for death = 0.75; P = .0011), and 10.2 months for those treated with bevacizumab alone. The median progression-free survival for the group treated with FOLFOX4 in combination with bevacizumab was 7.3 months, compared with 4.7 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for progression = 0.61; P < .0001), and 2.7 months for those treated with bevacizumab alone. The corresponding overall response rates were 22.7%, 8.6%, and 3.3%, respectively (P < .0001 for FOLFOX4 with bevacizumab v FOLFOX4 comparison). Bevacizumab was associated with hypertension, bleeding, and vomiting. CONCLUSION The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal.
This paper references
Cancer Statistics , 2004
LB Saltz
Interim analyses: the repeated confidence interval approach
C. Jennison (1989)
Cancer Statistics, 2004
A. Jemal (2004)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
P. Therasse (2000)
Discrete sequential boundaries for clinical trials
K. Lan (1983)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
J-Y. Douillard (2000)
Carboplatin (C) paclitaxel (T) rhumab-VEGF (AVF) may prolong survival in advanced nonsquamous lung cancer
DH Johnson (2001)
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
K. Margolin (2001)
Exact significance testing to establish treatment equivalence with ordered categorical data.
C. Mehta (1984)
A multiple testing procedure for clinical trials.
P. C. O'Brien (1979)
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.
D. Machover (1996)
Patterns of tumor progression during therapy with bevacizumab (BV) and chemotherapy (CT) for metastatic colorectal cancer (MCRC) and advanced non-small cell lung cancer (NSCLC)
F Kabbinavar (2001)
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
F. Kabbinavar (2003)
Evaluation of survival data and two new rank order statistics arising in its consideration.
N. Mantel (1966)
Therapies directed at vascular endothelial growth factor
P. Manley (2002)
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
M. Rothenberg (2003)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
L. Saltz (2000)
Regression Models and Life-Tables
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
F. Kabbinavar (2005)
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
R. Goldberg (2004)
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
M. Gordon (2001)
Patterns of tumor progression during therapy with bevacizumab (BV) and chemotherapy (CT) for metastatic colorectal cancer (MCRC) and advanced non-small cell lung cancer (NSCLC)
F Kabbinavar (2001)
Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer
M. Dong (2006)
Molecular and biological properties of vascular endothelial growth factor
N. Ferrara (1999)
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
J. Yang (2003)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
A. de Gramont (2000)

This paper is referenced by
Eficiencia de tratamientos oncológicos para tumores sólidos en España
I. Oyagüez (2013)
Evaluation of Hypertension and Proteinuria as Markers of Efficacy in Antiangiogenic Therapy for Metastatic Colorectal Cancer
L. Khoja (2014)
Non-adjuvant Single Low Dose Bevacizumab Intravitreal Injection Causes Resolution of Choroidal Metastases from Breast Carcinoma
Lizette Mowatt (2014)
Molecular Markers for Individualized Therapy in Colorectal Cancer: Progress Towards a Pharmacogenomics Array
Seonjoo Ahn (2009)
The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside
A. Zaniboni (2016)
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: A Japanese experience
Y. Ogata (2010)
Efficacy of repeated low-dose bevacizumab treatment with long-dosing interval for radiation-induced brain necrosis: A case report
X. Meng (2017)
Oncotargets and Therapy
Masao Kobayakawa ()
The Emerging Role of p38 Alpha in Cancer Specific Metabolism and Therapy: Analysis of Autophagic and Apoptotic Pathways in Response to Its Inhibition
A. Matrone (2013)
Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
G. Falchook (2014)
Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept
G. Giordano (2014)
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
N. Vasudev (2014)
Optimizing the management of metastatic colorectal cancer.
P. Comella (2010)
Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy.
K. Contractor (2012)
Applicability of Selective Data Collection to Cancer Clinical Studies for Supplemental Marketing Approvals
N. Sekine (2016)
A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer
S. Hasegawa (2017)
Metastatic colorectal cancer: current state and future directions.
M. Fakih (2015)
From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors
F. Zoratto (2014)
Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
J. Lee (2014)
Cost Considerations in the Evaluation and Treatment of Colorectal Cancer
V. Shankaran (2015)
Ranibizumab-induced retinal reperfusion and regression of neovascularization in diabetic retinopathy: An angiographic illustration
S. Chandra (2018)
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
B. Mohelníková-Duchoňová (2014)
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
D. Cunningham (2013)
Everolimus in colorectal cancer
I. Altomare (2013)
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
J. Ebos (2011)
Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk
F. Kabbinavar (2008)
Recurrent disease four years after surgery and adjuvant chemotherapy.
C. Pozzo (2008)
Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
T. Jakobs (2008)
The Development of Avastin
R. Mass (2008)
Curative Resection Following Neoadjuvant Chemotherapy Including a Molecularly Targeted Agent in Patients with Unresectable Colorectal Distant Metastases
J. Kim (2008)
Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study
G. Stathopoulos (2010)
Surfactant-based drug delivery systems for treating drug-resistant lung cancer
P. Kaur (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar